Premium
Short‐ and long‐term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/III A inhibitors: A meta‐analysis of randomized trials
Author(s) -
Nairooz Ramez,
Sardar Partha,
Amin Hossam,
Chatterjee Saurav,
Helmy Tarek,
Naidu Srihari S.
Publication year - 2015
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.25952
Subject(s) - bivalirudin , medicine , percutaneous coronary intervention , mace , conventional pci , odds ratio , myocardial infarction , randomized controlled trial , cardiology , diabetes mellitus , surgery , endocrinology
Background Diabetes patients undergoing percutaneous coronary intervention (PCI) have more complications than nondiabetes patients, including increased long‐term mortality. Use of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitors (GPI) in diabetes patients undergoing PCI and its effect on long‐term mortality were evaluated in few randomized trials, but with conflicting results. Methods We searched the literature for randomized controlled trials that compared heparin and GPI therapy with bivalirudin in diabetes patients undergoing PCI. The incidence of major adverse cardiovascular events (MACE), death from any cause, myocardial infarction (MI), urgent revascularization, major and minor bleeding (at 30 days), as well as all‐cause mortality at 1 year were included, and meta‐analysis was performed. Results A total of 5,137 patients with diabetes were included in four randomized trials. At 30 days, bivalirudin, compared with heparin and GPI, caused less major bleeding (odds ratio (OR), 0.68; 95% confidence interval (CI), 0.52–0.89; P = 0.005) and less minor bleeding (OR, 0.48; 95% CI, 0.41–0.57; P < 0.00001) and similar rates of MACE (OR, 0.87; 95% CI, 0.70–1.08; P = 0.21), MI (OR, 0.87; 95% CI, 0.68–1.10; P = 0.25), and urgent revascularization (OR, 1.12; 95% CI, 0.76–1.65; P = 0.57). Death from any cause at 30 day was numerically lower with bivalirudin use but not statistically significant (OR, 0.72; 95% CI, 0.46–1.13; P = 0.15). Mortality at 1 year was significantly lower in diabetes patients treated with bivalirudin compared with heparin and GPI (OR, 0.72; 95% CI, 0.52–0.99; P = 0.04). A secondary analysis suggests that the major bleeding benefit with bivalirudin may be driven by mandated use of GPI in heparin arm. Conclusion Among patients with diabetes undergoing PCI, bivalirudin caused less major and minor bleeding compared with heparin and GPI, with similar rates of MACE, death, MI, and urgent revascularization at 30 days, but significantly lower mortality rates at 1 year. © 2015 Wiley Periodicals, Inc.